Effects of nasal CPAP on simulated driving performance in patients with obstructive sleep apnoea

C F P George, A C Boudreau, A Smiley

Abstract

Background — Many patients with obstructive sleep apnoea (OSA) have difficulty in driving and experience increased automobile accidents. It has previously been shown that patients with OSA perform poorly on a laboratory based divided attention driving test (DADT).

Methods — Seventeen men with OSA of mean (SD) age 49.7 (11.2) years and an initial apnoea/hypopnoea index (AHI) of 73.0 (28.9) were restudied from one to 12 (mean (SD) 9.2 (4.2)) months after initiating treatment with nasal continuous positive airway pressure (CPAP) to examine the effects of treatment on DADT performance. Eighteen age and sex matched controls were also restudied 8.4 (3.4) months after their initial tests. Following a practice session, all subjects were given the DADT for 20 minutes before each daytime nap of the standard multiple sleep latency test (MSLT).

Results — Untreated patients with OSA, who performed much worse than controls in all measures, improved significantly on all measures of performance, particularly in tracking error which returned to the level of controls in all but one patient. Changes in performance were much greater for patients with OSA than for controls in tracking error (mean difference 106 (95% CI 75 to 135) cm), sleep latency/MSLT (5.3 (95% CI 2.7 to 8.0) min), number of correct responses (1.2 (95% CI 0.4 to 1.9)), number of missed responses (1.7 (95% CI 0.9 to 2.3)), and number out of bounds (10.0 (95% CI 7.9 to 13.6)), but not for response time (0.1 (95% CI 0.3 to 0.2) s). Improvement in tracking error was highly correlated with improvement in sleepiness (r = 0.65).

Conclusions — Impairment in laboratory driving performance skills in patients with OSA is reversed by successful treatment with nasal CPAP. Changes in daytime sleepiness account for some but not all of the improvement. (Thorax 1997;52:648–653)

Keywords: sleep apnoea, driving, automobile accidents, performance.

As a group, patients with obstructive sleep apnoea (OSA) have increased automobile accidents when compared with control groups or population data. Increasingly, physicians are being asked to make recommendations about a patient’s ability to drive and, in some jurisdictions, are required by law to report sleepy patients. While the recent ATS statement on sleep apnoea and driving makes recommendations on driving, it would be helpful to have a safe, reliable and valid laboratory based test of driving performance to aid in the process. Recently we have been using a laboratory based divided attention driving task (DADT) which is sensitive to impairment due to alcohol. When given to a group of patients with OSA we found that at least half of the group performed as poorly, if not worse, than controls impaired by alcohol. Since most patients report improvement or even resolution of their OSA symptoms with treatment, we wondered whether continuous positive airway pressure (CPAP) might improve and/or normalise DADT performance and sleepiness.

Methods

SUBJECTS

Control subjects and patients with OSA from a previous protocol6 made up the study population. Entry criteria were as previously reported, the patient group comprising subjects presenting with snoring and/or daytime sleepiness to the London Health Sciences Centre Sleep Disorders Clinic for evaluation of possible sleep apnoea. Following history and physical examination, those patients suspected clinically of having sleep apnoea were invited to participate in the study. In an attempt to minimise selection bias, consecutive new patients were invited to participate. Exclusion criteria were: (a) no driver’s licence (currently, or in the past); (b) presence of physical disability (muscle weakness) which could independently affect driving performance; (c) use of hypnotics/sedatives which could produce sleepiness and/or impair performance; (d) use of stimulants which could decrease sleepiness; (e) diagnosis other than OSA; (f) clinical or laboratory evidence of hypothyroidism; and (g) apnoea/hypopnoea index of less than 15. Subjective sleepiness was neither a necessary nor a sufficient condition for entry to the study. At the time the first study began, the work of Young et al8 had not been published and it was assumed that the prevalence of sleep apnoea was much lower in women so women were not included.

Age matched control subjects were recruited from the community by advertisement. To reduce the possibility of differences in driving
Effects of nasal CPAP on driving performance in OSA

Lane position – also referred to as lane position variability – and response time to targets. Other measures include the number of correct, incorrect and missed targets, and the number of times the vehicle is out of bounds.

Polysomnography
Standard overnight polysomnography included electroencephalographic (EEG) data (C1/A2, C4/A1, O2/A1), electro-oculographic (EOG) data and submental electromyographic (EMG) data, bilateral tibialis anterior EMG, expired CO₂ (qualitative) or thermocouple at nose and mouth to index airflow, respiration (rib cage and abdominal respiratory inductive plethysmography using Respitrace), and oxygen saturation with ear oximetry (Ohmeda 3700).

Multiple sleep latency testing (MSLT)
Four naps were carried out and sleep onset was scored from three consecutive epochs of stage 1 sleep or one epoch of any other stage.

Protocol for assessments
All subjects underwent overnight polysomnography followed by repeated DADT. Each performance test was followed by 20 minute naps as part of the MSLT. The time in bed prior to daytime testing was fixed at eight hours regardless of time asleep. Patients with OSA slept with nasal CPAP at the preset pressure used at home and no adjustments were made unless there was obvious apnoea. Control subjects slept at home on the night prior to (repeat) testing and were instructed to have their usual sleep period time. They reported to the laboratory at 08.00 hours.

Following breakfast all subjects (controls and those with OSA) underwent a practice session on the divided attention driving task. As was the case on initial testing, the practice consisted of six five-minute tests. Then, before each of the four naps of the MSLT, a 20 minute divided attention driving test took place and the outcome measures were averaged for the four trials in the day.

Statistical analysis
To determine differences during practice runs in the main performance measures, repeated measures analysis of variance was used. Polynomial tests of order were used to test for trends, the first polynomial testing for linear trends. Unpaired t tests were used to compare changes from baseline in patients with OSA to changes from baseline in controls for the main outcome measures of tracking error and response time as well as the secondary measures of correct and missed targets and times out of bounds. Linear regression was used to examine the relationship between change in sleepiness (as measured by MSLT) and performance measures. Paired and unpaired t tests were used to compare ages and measures of sleep...
fragmentation. Comparison of sleep stages were restricted to slow wave sleep (SWS, stages 3 and 4 combined) and REM sleep.

**Results**

Seventeen patients with OSA and 18 control subjects were retested. The two groups were similar in age (controls 45.6 (14.6) years, patients with OSA 49.7 (11.2) years) and their ages did not differ from the larger groups from which they were drawn (see above).

**Polysomnography**

The results of the sleep studies for each test for the two groups are shown in table 1. Untreated patients with OSA had considerable sleep fragmentation with significantly increased microarousals per hour of sleep (67.5 (28.5) versus 9.9 (7.7), p <0.001) and awakenings (32.8 (16.7) versus 27.4 (9.2), p <0.05) compared with controls. Sleep improved markedly with CPAP treatment and there were no significant differences in overnight sleep measures between the CPAP treated group and the controls.

CPAP sleep studies and repeat divided attention driving tests were performed 9.2 (4.2) months (range 1–12) after initiating treatment and control subjects were retested 8.4 (3.4) months (range 2–12) after their first studies. Reported compliance with CPAP was high with all subjects claiming CPAP use of six or more hours for six or more nights per week.

**Performance Learning Effects**

The results from the practice trials are shown in fig 2. Trial 1 involved visual search alone, trial 2 was tracking alone, and trials 3–6 involved both tasks. For control subjects there were no differences in performance in runs 3–6 (within-test learning) or between practice assessments (control 1 versus control 2; fig 2). The same applied to patients with OSA except that the magnitude of the tracking error was much less in those treated with CPAP than in the untreated patients (p <0.001, fig 2C). Regardless of condition, patients with OSA learned at the same rate as the control subjects.

---

**Table 1** Comparison of age, apnoea index and sleep structure in control subjects and patients with obstructive sleep apnoea (OSA), before and after treatment with CPAP

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>OSA</th>
<th>OSA-CPAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>46.1 (15.1)</td>
<td>49.3 (5.1)</td>
<td>49.7 (11.2)</td>
</tr>
<tr>
<td>Arousal/hypopnoea index</td>
<td>3.1 (3.1)</td>
<td>73.0 (28.9)*</td>
<td>6.5 (7.1)*</td>
</tr>
<tr>
<td>Awakening</td>
<td>27.4 (9.2)</td>
<td>32.8 (16.7)*</td>
<td>26.2 (12.2)*</td>
</tr>
<tr>
<td>Stage changes/hour</td>
<td>17.3 (15.5)</td>
<td>18.4 (6.9)</td>
<td>13.7 (3.9)*</td>
</tr>
<tr>
<td>Arousal/hour</td>
<td>9.9 (7.7)</td>
<td>67.5 (28.5)*</td>
<td>11.4 (5.9)*</td>
</tr>
<tr>
<td>Sleep stages (% TST)</td>
<td>8.4 (4.1)</td>
<td>10.6 (6.9)</td>
<td>9.3 (6.4)</td>
</tr>
<tr>
<td>SWS (3 + 4)</td>
<td>18.5 (7.2)</td>
<td>6.9 (6.6)*</td>
<td>15.0 (5.8)*</td>
</tr>
<tr>
<td>REM</td>
<td>19.0 (6.4)</td>
<td>13.2 (6.3)*</td>
<td>22.1 (6.1)*</td>
</tr>
</tbody>
</table>

*p<0.05 OSA versus control. †p<0.05 OSA-CPAP versus OSA.

---

**Figure 2** Effect of practice on performance measures – tracking error (A and C) and response time (B and D) – in control subjects (A and B) and patients with OSA (C and D). The results are represented as means with one standard deviation. There was no strong learning effect for either measure.
Effects of nasal CPAP on driving performance in OSA

Table 2 Mean (SE) repeated daytime sleep and performance measures in controls and patients with obstructive sleep apnoea (OSA) before and after treatment with CPAP

<table>
<thead>
<tr>
<th>Control 1 (C1)</th>
<th>Control 2 (C2)</th>
<th>OSA (OSA1)</th>
<th>OSA-CPP (OSA2)</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSLT (min)</td>
<td>12.3 (0.9)</td>
<td>12.9 (0.8)</td>
<td>7.2 (0.8)</td>
<td>13.2 (0.8)</td>
</tr>
<tr>
<td>Tracking error (cm)</td>
<td>82 (4.8)</td>
<td>88 (6.9)</td>
<td>228 (17.2)</td>
<td>113 (0.5)</td>
</tr>
<tr>
<td>Response time (s)</td>
<td>2.6 (0.1)</td>
<td>2.3 (0.1)</td>
<td>3.2 (0.1)</td>
<td>2.8 (0.1)</td>
</tr>
<tr>
<td>Correct responses (n)</td>
<td>39.3 (0.1)</td>
<td>39.7 (0.1)</td>
<td>36.2 (0.5)</td>
<td>37.8 (0.5)</td>
</tr>
<tr>
<td>Missed responses (n)</td>
<td>0.6 (0.1)</td>
<td>0.4 (0.1)</td>
<td>3.7 (0.5)</td>
<td>2.2 (0.5)</td>
</tr>
<tr>
<td>Out of bounds (n)</td>
<td>0.1 (0.1)</td>
<td>0.1 (0.1)</td>
<td>12.6 (2.1)</td>
<td>2.6 (1.2)</td>
</tr>
<tr>
<td>C2-C1</td>
<td>0.6 (0.9)</td>
<td>5.9 (1.0)</td>
<td>0.6 (0.9)</td>
<td>5.6 (1.0)</td>
</tr>
<tr>
<td>OSA2-OSA1</td>
<td>-0.3 (0.1)</td>
<td>-0.4 (0.1)</td>
<td>-0.2 (0.1)</td>
<td>1.5 (0.4)</td>
</tr>
<tr>
<td>p value</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.05</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

MSLT = multiple sleep latency time.

missed responses (1.7 (95% CI 0.9 to 2.3)), and number of times out of bounds (10.0 (95% CI 7.9 to 13.6)) but not for response time (0.1 (95% CI −0.3 to 0.2) s). Performance in the control subjects showed no significant test–retest changes in primary or secondary outcome measures (table 2). Figure 3 shows the typical improvement in tracking error for a patient with OSA whose initial performance was impaired. Figure 4 shows the mean improvement for all patients and demonstrates that tracking error remained poor in only one patient with OSA.

SLEEPINESS

As expected, sleepiness as measured by MSLT was unchanged in controls (12.3 (6) versus 12.9 (5.9) min, p = 0.6) but improved significantly in patients with CPAP treatment (7.2 (6) versus 13.2 (6.7) min, p <0.001). There was no difference in MSLT between treated patients with OSA and controls.

CORRELATIONS

Change (improvement) in tracking error was highly correlated with improvement in sleepiness (as measured by MSLT) as seen in fig 5.
Improvements in other outcome measures were not correlated with changes in sleepiness. While the change in MSLT accounts for 43% of the variance in tracking error improvement, factors other than sleepiness are obviously involved in determining driving performance.

**Discussion**

Treatment of apnoea with nasal CPAP resulted in significant improvement in simulated driving performance in this group of patients with OSA. Nocturnal sleep returned to normal and only one patient had any residual daytime complaints. Both primary (tracking) and secondary (response time, correct responses) performance measures improved significantly with treatment and only correct and missed responses, while improved, remained statistically different from controls.

With any performance test there is a learning curve and improvements between testings could be attributed to practice effects. To address this, practice runs were given to both groups at both points which, we believe, represents a particular strength of this study. Both controls and patients demonstrated a similar rate of learning when they were first tested. As there was no improvement in control subjects with repeat testing we feel that the improvement in performance can be attributed to the beneficial effect of nasal CPAP on sleep and breathing.

While all but one patient returned to normal performance, the time course of improvement cannot be determined in this study as subjects had repeated testing on only a single occasion and the time between tests was not the same for all subjects. Previous work by Lamphere and colleagues has shown that sleepiness improves within two weeks of treatment with CPAP. Cognitive function also improves with treatment but may take longer. Although our patients were studied an average of nine months after starting treatment, two were retested after four weeks of CPAP treatment and their tracking error returned to the control range. The others who were tested later might also have improved within 2–4 weeks but further study with measurements at specified times after initiating CPAP treatment are necessary to answer this conclusively. In our patients the reported rate of compliance was high although objective measures of CPAP compliance are necessary to determine the time course and degree of improvement in performance.

One patient remained very poor in his divided attention performance. This patient was discovered to have significant underlying periodic limb movement disorder which disrupted his sleep and presumably produced daytime sleepiness. This was not recognised on his initial diagnostic study when sleep disruption due to severe apnoea obscured this finding. On his CPAP titration study there were periodic limb movements noted but they were not associated with arousal, probably because of the large amounts of rebound slow wave sleep from which arousal would have been blunted. This case highlights the need for follow up in patients with OSA once CPAP has been prescribed. Although sleep apnoea is one of the commonest causes of daytime sleepiness, there may be co-existing conditions which produce ongoing sleepiness and influence daytime function.

Previous studies have shown improvement in performance with CPAP. Findley was the first to show improvement in performance on the computer based program Steer Clear. This task, initially described as a driving simulator, is really a choice reaction task requiring sustained vigilance. Both Findley and Engleman et al reported improvement in performance on this task with CPAP treatment. Haraldsson and colleagues, using an advanced car driving simulator, have reported both short and long term improvement in driving performance in patients treated with uvulopalatopharyngoplasty. Thus, improvement in performance in this study with CPAP treatment was not unexpected. Nonetheless it is reassuring to see improvement in virtually every patient in this study. However, application of these results to the sleep apnoea population at large is somewhat limited since all subjects in this study were male. No women were enrolled because, at the time when the initial study was started, the work of Young et al had not been published and the International Classification of Sleep Disorders listed a much higher male to female ratio for OSA.

Based on clinical history, many patients with OSA report no difficulties with their ability to drive. In this study there were patients whose pretreatment performance was not different from the control subjects. Others, however, were quite impaired. The clinical history may show differences in self-reported automobile accidents after CPAP treatment. Suratt and Findley found a fall in self-reported accidents or near accidents from 41% to 5% of a group of 22 patients treated with CPAP. In contrast, we recently reported marked differences in the opposite direction) in self-reported driving difficulties between the initial clinician visit and follow up after treatment with CPAP in patients with OSA. Patients may be reluctant to admit difficulties with driving because of the potential for loss of licence. Such discrepancies complicate the task of determining ability to operate a motor vehicle since most decisions are based on subjective data. Objective measures such as the DADT may become important additions to the process of determining ability to drive. Comparisons with subjects’ driving records and/or on the road testing will be needed before this laboratory based test can be used in day to day clinical management. Such comparisons are now underway.

The authors wish to thank Sandra Hallo and Lynne Babin for technical assistance and Darlene Taranik for secretarial expertise.

This study was supported by the Ontario Thoracic Society, the Medical Research Council of Canada, and the Ontario Ministry of Transportation.

Effects of nasal CPAP on driving performance in OSA

Effects of nasal CPAP on simulated driving performance in patients with obstructive sleep apnoea.
C F George, A C Boudreau and A Smiley

Thorax 1997 52: 648-653
doi: 10.1136/thx.52.7.648

Updated information and services can be found at:
http://thorax.bmj.com/content/52/7/648

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/